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Abstract
Previously, we highlighted induction of an integrated stress response (ISR) gene program
in skeletal muscle of pigs treated with a beta-adrenergic agonist. Hence we tested the
hypothesis that the ER-stress inhibitor, sodium 4-phenylbutyrate (PBA), would inhibit Clen-
buterol-mediated muscle growth and reduce expression of genes that are known indicators
of an ISR in mice. Clenbuterol (1mg/kg/day) administered to C57BL6/J mice for 21 days
increased body weight (p<0.001), muscle weights (p<0.01), and muscle fibre diameters
(p<0.05). Co-administration of PBA (100mg/kg/day) did not alter the Clenbuterol-mediated
phenotype, nor did PBA alone have any effects compared to that of the vehicle treated
mice. Clenbuterol increased skeletal muscle mRNA expression of phosphoserine amino
transferase 1 (PSAT1, p<0.001) and cyclophillin A (p<0.01) at day 3, but not day 7. Clenbu-
terol decreased mRNA expression of activating transcription factor (ATF) 4 and ATF5 at day
3 (p<0.05) and day 7 (p<0.01), X-box binding protein 1 (XBP1) variant 2 mRNA at day 3 only
(p<0.01) and DNA damage inducible transcript 3 (DDIT3/CHOP) mRNA at day 7 only
(p<0.05). Co-administration of PBA had no effect on Clenbuterol-induced changes in skele-
tal muscle gene expression. In contrast, treatment of C2C12 myotubes with 5mM PBA (8hr)
attenuated the thapsigargin-induced ISR gene program. Prolonged (24-48hr) treatment with
PBA caused atrophy (p<0.01), reduced neoprotein synthesis (p<0.0001) and decreased
expression of myogenin and fast myosin heavy chain genes (p<0.01), indicating an inhibi-
tion of myogenic differentiation. In summary, Clenbuterol did not induce an ISR gene pro-
gram in mouse muscle. On the contrary, it reduced expression of a number of ISR genes,
but it increased expression of PSAT1 mRNA. Co-administration of PBA had no effect on
Clenbuterol-mediated muscle growth or gene expression in mice, whereas PBA did inhibit
thapsigargin-induced ISR gene expression in cultured C2C12 cells and appeared to inhibit
myogenic differentiation, independent of altering ISR gene expression.
Introduction
Retention of lean body mass is largely achieved by maintaining rates of skeletal muscle protein
synthesis and degradation in equilibrium [1]. The ability to retain skeletal muscle mass is
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impaired with ageing [2], which is associated with reduced mobility and increased all-cause
mortality [3–5]. The identification of conserved mechanisms regulating skeletal muscle pro-
tein metabolism are required for the development of novel therapeutics controlling muscle
mass.
The integrated stress response (ISR) is a highly conserved frontline protection against a
diverse array of stressors, such as amino acid limitation, viral infection, or an accumulation of
miss-folded proteins [6]. Phosphorylation of eukaryotic translation initiation factor 2 alpha
(eIF2α) is considered a central event of the ISR, which decreases global protein synthesis,
whilst selectively promoting translation of activating transcription factor 4 (ATF4). The mam-
malian target of rapamycin (mTORC1), a potent stimulator of protein synthesis [6], can also
regulate a post-transcriptional increase in ATF4 expression independent of eIF2α phosphory-
lation [7]. Depending on the severity of stress, the ISR leads to transcription of functionally
related cohorts of ATF4 target genes, which attempt to restore cellular homeostasis or, if
homeostasis cannot be resumed, initiate programmed cell death [8]. Genes involved in this
adaptive response regulate several aspects of protein metabolism, namely amino acid biosyn-
thesis, protein translation, and amino acid transport. Thus, the ISR is a potentially exploitable
mechanism to manipulate skeletal muscle growth and metabolism.
We recently demonstrated induction of an ISR gene program in skeletal muscle of pigs
treated with a beta-adrenergic agonist (BA) [9], a potent class of muscle anabolic drug. Specifi-
cally, treatment with a BA triggered a co-ordinated and temporal increase in expression of 20
+ genes that are known transcriptional targets of ATF4, the best-characterized central effector
of the ISR gene program. The majority of these genes were involved in amino acid biosynthesis
(Phgdh, Psat1, Psph, Pck2, Asns, Arg2, Ass1, Gpt2), tRNA charging (Sars, Tars, Gars, Wars, Iars,
Aars), and amino acid transport (Slc3a2, Slc7a1, Slc5a1), as well as inhibition of cellular growth
(Sesn2 and Cdkn1a). Importantly, expression of these BA-inducible genes peaked 3 days fol-
lowing the initiation of treatment, and declined thereafter. Several other studies have revealed
an ISR in skeletal muscle of rodents and humans following exercise [10,11], inactivity [12,13]
and hypertrophic growth [14,15]. However, the role and cause of an ISR during skeletal muscle
growth remains unknown. It is possible that an increased demand for amino acids (caused by
increased protein synthesis) triggers an ISR. Alternatively, an ISR could occur due to an accu-
mulation of miss-folded proteins, i.e. endoplasmic reticulum (ER) stress, caused by over-
reaching the protein synthetic capacity of the cell. Although the precise role of the ER in the
maintenance of skeletal muscle mass is unknown, ER-stress (induced by treatment with thap-
sigargin) causes anabolic resistance in cultured muscle cells through blockade of mTOR-medi-
ated protein translation, exemplifying a link between ER homeostasis and protein metabolism
in muscle cells [15].
Sodium-4 Phenylbutyrate (PBA) is a short chain aromatic fatty acid, capable of stabilizing
miss-folded proteins and therefore limiting ER-stress [16]. Originally discovered as a nitrogen
scavenging treatment for urea cycle disorders [17,18], numerous applications of PBA are rap-
idly emerging [16,19], with pre-clinical and clinical trials examining its therapeutic role in the
treatment of spinal muscular atrophy [20], beta-thalassemia [21], cancer [22,23], Huntington’s
disease [24], cystic fibrosis [25], type 2 diabetes [26] and immune disorders [27]. The precise
mechanisms by which PBA is protective across such a diverse spectrum of pathological states
remains poorly understood but the use of PBA to alleviate ER stress constitutes the majority of
recently published work on this small molecule, affirming its role as an ER-stress inhibitor in
biomedical research [16,19].
Surprisingly, administration of PBA has previously been shown to be detrimental to the
maintenance of muscle mass in tumour bearing but also non-tumour bearing mice [28]. This
is largely counter-intuitive given that stabilization of protein folding and maintenance of ER-
PBA and Clenbuterol-mediated muscle growth
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function would be expected to sustain protein homeostasis, not disrupt it, but it does fit with
the idea suggested by our observations in BA treated pigs, that a certain degree of ER-stress is
required to sustain muscle growth. To explore this further, we tested the hypothesis that Clen-
buterol-mediated muscle growth would be inhibited by co-administration of the ER-stress
inhibitor, PBA, using a dose (100mg/kg/d) previously shown to inhibit ER-stress in cachexic
mice [28]. The identification of conserved mechanisms controlling skeletal muscle mass is
required to develop novel therapeutic strategies against muscle wasting conditions, which
remains a major unmet clinical need for several pathological conditions [29].
Materials and methods
Compounds
For in vivo use, Clenbuterol Hydrochloride (CLEN; CAS# 21898-19-1; Sigma Aldrich UK;
Lot# BCBQ2163V) and Sodium 4-Phenylbutyrate (PBA; CAS# 1716-12-7; Source BioScience
PLC UK; Lot# 31008) were dissolved in Phosphate Buffered Saline (Sigma Aldrich; PBS), fil-
ter-sterilized (through a 0.2μm filter) and frozen in aliquots at -20˚C. A separate aliquot was
used each day. CLEN and PBA were stored as 2x concentrated stocks (0.2μg/μl and 20μg/μl,
respectively) and diluted 1:1 with either PBS or the combining compound (i.e. CLEN with
PBA) on the day of use.
For in vitro use, PBA and Puromycin (Fisher UK) were dissolved in PBS, whereas Thapsi-
gargin (Sigma Aldrich UK) was dissolved in Dimethyl sulfoxide (DMSO). Dissolved com-
pounds were filter-sterilized (through a 0.2μm filter) and frozen in aliquots at -20˚C. All
compounds were diluted 1:1000 into culture media to achieve 5mM PBA, 1μM Puromcyin,
and 250nM Thapsigargin. The corresponding treatment vehicle was used for controls. DMSO
accounted for 0.1% (v/v) of the culture media in Thapsigargin experiments.
Effect of Clenbuterol and PBA in vivo
C57BL6/J male mice (approximately 5–6 weeks of age; Charles River UK Ltd.) were singly
housed at 21 ± 1˚C on a 12hr light: 12hr dark photoperiod (lights off at 19:00), with ad libitum
access to food and water. Mice were fed Teklad Global 18% Protein Rodent Diet (Envigo). Fol-
lowing 7 days acclimatization to singly housed conditions, mice (n = 6 per treatment, per time
point) were administered a daily subcutaneous injection (at approximately 9am) for 3, 7 or 21
days with one of the following: Clenbuterol (1mg/kg/day), Clenbuterol (1mg/kg/day) + PBA
(100mg/kg/day [28]), PBA only (100mg/kg/day [28]), or the vehicle control (phosphate buff-
ered saline). Body weight and feed intake was monitored daily.
Initial responses to the treatment were carefully monitored for 24 hours in a Comprehen-
sive Lab Animal Monitoring System (CLAMS; Linton Instrumentation, Linton, UK, and
Columbus Instruments, Columbus, OH, USA). Changes in physical activity (measured by
infrared beam breaks) and feeding behavior permitted deduction of adverse reactions to the
administered compound. All animals were acclimatized to the CLAMS system for a 24hr
period immediately preceding the 24hr data collection period.
Following 3, 7 or 21 days of treatment, animals were euthanized by cervical dislocation. The
Tibialis Anterior (TA), Extensor Digitorum Longus (EDL), Gastrocnemius (GA) and Soleus
(SOL) muscles were carefully dissected and weighed (wet weight). The GA muscle was snap
frozen on solid carbon dioxide, before being stored at -80˚C for analysis of gene expression.
The TA muscle was coated in optimal cutting temperature (OCT) compound and then snap
frozen in dry ice-chilled isopentane, before being stored at -80˚C for analysis of muscle fibre
diameters.
PBA and Clenbuterol-mediated muscle growth
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All animal procedures were approved by The University of Nottingham Ethical Review
Committee and conducted in accordance with the UK Animals (Scientific Procedures) Act of
1986 (Project License PPL 40/3604).
RNA extraction and quantitative-RT-PCR
Using a liquid nitrogen-cooled pestle and mortar, a gastrocnemius muscle from each animal
per treatment at day 3 and 7 (n = 6 per treatment) was crushed to a fine powder. Total RNA
was extracted from 20mg of crushed muscle using the RNeasy Fibrous Tissue Mini Kit (Qia-
gen) according to manufacturer’s instructions.
Total RNA from cultured C2C12 myotubes was extracted as previously described [30]
using the High Pure RNA Isolation Kit (Roche).
First strand cDNA synthesis was performed on 500ng RNA using the Transcriptor First
Strand cDNA synthesis Kit (Roche) according to manufacturer’s instructions. Quantitative-
RT-PCR was conducted using the SYBR-green method as previously described [30]. Relative
transcript abundance was determined from a standard curve and normalised against total
cDNA content of the PCR reaction using the established oligreen method [31] as previously
described [30]. Oligonucleotide sequences are shown in Table 1. Sequences for myosin heavy
chain isoforms and myogenin have been published elsewhere [30].
Muscle fibre diameter analysis
Sections from the mid-belly of the TA muscle were cryosectioned at -24˚C, at a thickness of
12μm. Sections were air-dried for one hour and then stained with 5μg/ml Wheat Germ Agglu-
tinin (WGA) containing an Alexa Fluor1 488 Conjugate (ThermoFisher #W11261) for 20
minutes. Sections were then washed with phosphate buffered saline for 2 x 5 minutes, air-
dried and then mounted with Fluoroshield™ containing DAPI overnight. Five fields of view
(each containing ~100 fibres) from a single section per muscle were imaged at 20x magnifica-
tion. Sections from 6 TA muscles per treatment were analysed, which equated to ~3000 fibres
per treatment being measured. Muscle fibre perimeters were manually traced and the minimal
feret’s diameter was calculated using image-J software. Minimal feret’s diameter of individual
muscle fibres is considered superior to measuring muscle fibre cross-sectional area because it
Table 1. Murine oligonucleotide sequences for q-RT-PCR.
Gene Forward Reverse
ATF4 TGGCCAAGCACTTGAAACCT GCCAAGCCATCATCCATAGC
ATF5 GAGAGGGAGGTCTCGTGTACGT GATGGACTGGATAGGAAAGTGGAA
DDIT1 CCCCGGACCTGCACTGT GACTTAAGGCAGGATCCTTCCA
DDIT3 GAAGAGGAAGAATCAAAAACCTTCA GCCCTGGCTCCTCTGTCA
SESN2 TCAGCGAGGTCAACAAGTTACTG CAAGGCCTGGATATGCTCCTT
CEBPG GAGGCGCAGGTACATGTGAA CCTTTGCCAACACAGAATAGGTAGA
PPIA TGATGGCGAGCCCTTGG TCTGCTGTCTTTGGAACTTTGTC
PHGDH CGTGAACTTGGTGAACGCTAAG GTGGGAGGTGGTGACATTGAG
PSAT1 CGTGCTTCAGCATCTACGTCAT GCCCCGCCGTTGTTCT
PSPH GGCATAAGGGAGCTGGTAAGC GCCACCAGAGATGAGGAACAC
ASNS TGAAGGAACTCTACCTGTTTGATGTT GGGACTCTCAGTTCGAGACCGT
PCK2 GCAGAGCACATGCTGATTTTG GGAAAGCAGCTGCCACGTA
Total XBP1 AAGAACACGCTTGGGAATGG ACTCCCCTTGGCCTCCAC
XBP1 variant 1 (unspliced) CCGCAGCACTCAGACTATGTG CCCAAAAGGATATCAGACTCAGAATC
XBP1 variant 2 (spliced) GAGTCCGCAGCAGGTG GTGTCAGAGTCCATGGGA
https://doi.org/10.1371/journal.pone.0201481.t001
PBA and Clenbuterol-mediated muscle growth
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is less influenced by differences in the orientation of the muscle when sectioning [32]. The
treatment groups were blinded to the investigator during the analysis.
Cell culture
C2C12 murine skeletal muscle myoblasts [33] were cultured as previously described [30].
Briefly, myoblasts were cultured in growth media (Dulbecco’s Modified Eagle’s Medium
(DMEM), 10% fetal bovine serum, 1% penicillin streptomycin; Sigma-Aldrich UK) and
encouraged to differentiate at near confluence by switching to differentiation media (DMEM,
2% horse serum, 1% penicillin streptomycin; Sigma-Aldrich UK). Differentiation media was
replaced every other day. Cells were incubated at 37˚C, with 5% CO2 and atmospheric oxygen
(~21%). Pharmacological treatments on myotubes were normally conducted on 4-day differ-
entiated cells, whereby substantial cell fusion had already occurred. Treatments added to dif-
ferentiating myoblasts were initiated at near confluence (day 0) when the media was switched
to differentiation medium.
Myotube size assays
Two methods of myotube size assessment were conducted to robustly characterize the effects
of PBA and serum content on myotube atrophy/hypertrophy.
Method 1. C2C12 myoblasts were transiently transfected with a Myh4-promoter driven
ZsGreen reporter construct, as previously described [34]. We have demonstrated that expression
of the Myh4 gene (encoding myosin heavy chain IIB) is restricted to fully differentiated myotubes
[30] and activity of the Myh4 promoter, as detected by a green fluorescent protein (ZsGreen), in
living C2C12 cells is a ‘real-time’ biomarker of mature myotubes in culture [34]. Green fluoresc-
ing myotubes (independent of nuclei number) were imaged pre-, during and post- treatment to
assess transient changes in average myotube width (repeated measures per well). Measurements
were conducted (using Image-J) at approximately 25, 50 and 75% of the total myotube length on
10 myotubes per field of view. Five random fields of view per well (on a 24-well plate) were ana-
lysed, providing an average myotube width of 50 myotubes per well and 150 myotubes per treat-
ment. The investigator was blinded to the treatment groups during analysis.
Method 2. C2C12 myotubes, defined as a MyHC expressing cell containing 2 or more
nuclei, were stained, imaged and measured. Briefly, culture media was removed and cells were
washed with warm PBS before being fixed in ice-cold methanol for 5 minutes. Cells were
washed with room temperature PBS before incubation with primary blocking solution (PBS
with 10% horse serum and 0.1% Triton-X; Sigma Aldrich) for 1 hour. Cells were then incubated
overnight with the MF20 antibody (1:1000; Developmental Studies Hybridoma Bank, The Uni-
versity of Iowa) against total myosin heavy chain in secondary blocking solution (PBS, 10%
horse serum, 0.05% Triton-X). Cells were washed 3 times with PBS for 5 minutes each time, fol-
lowed by a 2-hour incubation with anti-mouse Alexa Fluor 488 (1:1000; #A21121 Invitrogen) in
secondary blocking solution. Cells were washed 3 times with PBS and then incubated with PBS
containing propodium iodide (1:3000; Sigma-Aldrich) for 5 minutes to fluorescently label the
cell nuclei. Cells were further washed in PBS and then stored in PBS, with protection from light,
at 4˚C until imaged. Measurements were conducted as described in Method 1 above. To deter-
mine average nuclei number, nuclei were counted in 5 random fields of view per well.
SUnSET assay on C2C12 cells
Using Puromycin, which incorporates into nascent peptide chains, the SUnSET assay [35] was
used herein to quantify global neoprotein synthesis in cultured cells. Following 24 or 48hrs of
treatment, puromycin was added to the culture media (final concentration of 1μM) for exactly
PBA and Clenbuterol-mediated muscle growth
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30 minutes prior to harvesting the cells in 150μl 1x Laemmli buffer (containing protease and
phosphatase inhibitors; Roche) per well of a 24-well plate. Protein concentration was normal-
ised to a constant weight/volume and 10μg protein was electrophoresed on 4–15% acrylamide
gels (BioRad Criterion TGX). Proteins were wet-transferred to a nitrocellulose membrane,
probed for anti-puromycin (1:1000; MerkMillipore MABE343, clone 12D10) overnight, fol-
lowed by anti-mouse (1:25000; GE Health Care) for 90 minutes. Bands were visualised using
ECL select detection reagent (GE Health Care) and exposing the membrane to photographic
film in a dark room. Densitometry of each lane (i.e. all bands) indicated the amount of puro-
mycin incorporated into newly synthesized proteins within a 30-minute window.
Statistical analyses
Statistical analyses were performed using Prism (Version 7). All data generated by in vivo
experiments were assessed by a two-way analysis of variance (ANOVA) for significant effects
of treatment, time or an interaction (treatment x time; treatment x treatment). Cell culture
experiments were assessed by unpaired t-tests (if using a single treatment at a single time
point) or by two-way ANOVA (if using multiple time points or combined treatments). Sidak’s
or Tukey’s post hoc analysis was conducted where appropriate. Statistical significance was
accepted if p<0.05. All data are presented as mean ± standard error of the mean.
Results
PBA does not modify Clenbuterol-mediated improvements in weight gain
and feed efficiency
Despite no change in food intake, mice administered daily injections of Clenbuterol for 21 days,
with or without PBA, gained approximately twice as much weight as the control or PBA-only
treated mice (Fig 1A–1C; p<0.001). Consequently, gross feed conversion efficiency (gain:feed)
was improved approximately 2-fold with Clenbuterol (Fig 1D; p<0.0001), with no effect of PBA.
Unexpectedly, the initial administration of Clenbuterol, with or without PBA, caused a tem-
porary reduction in 24-hour food intake (Fig 1E; interaction p<0.0001) and ambulatory activ-
ity (Fig 1G; interaction p<0.0001), which had not previously been described. This response
was not apparent when the same parameters were assessed at day 7 (Fig 1F–1H), neither were
they apparent from the home cage food intake data on day 2 (data not shown).
PBA does not modify Clenbuterol-mediated increases in muscle mass
Clenbuterol significantly (p<0.01) increased the weight of individual hind limb muscles
(Tibialis anterior, Extensor digitorum longus, Soleus, and Gastrocnemius), with no effect of co-
administering PBA (Fig 2A–2D). This was confirmed by an increase in the average minimal
feret’s diameter of Tibalis anterior muscle fibres from Clenbuterol treated animals, with no
effect of PBA (Fig 2E–2G). Whilst PBA alone did not significantly (p>0.05) decrease the aver-
age muscle fibre diameter in comparison to that of the control, there was a notable leftward
shift in the frequency of smaller muscle fibres at the expense of larger ones compared to that of
the control and Clenbuterol treated groups (Fig 2E).
Molecular effects of Clenbuterol and PBA on expression of integrated
stress-responsive (ISR) genes
Previously published data demonstrated that treatment with a beta-adrenergic agonist induced
increased expression of amino acid biosynthesis and other integrated stress-responsive (ISR)
genes in pig skeletal muscle, peaking between days 3 and 7 of treatment [9]. We therefore
PBA and Clenbuterol-mediated muscle growth
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assessed changes in expression of these genes at the same time points in mice treated with
Clenbuterol (with and without PBA).
Of the serine biosynthesis pathway genes (Phgdh, Psat1 and Psph), only Psat1 displayed a
significant increase in mRNA expression by Clenbuterol at day 3 (p<0.001), but not day 7,
with no effect of co-administering PBA (Fig 3A and 3B). Cyclophilin A (Ppia), which is
involved in protein folding, was also increased by Clenbuterol treatment at day 3 (p<0.01), but
not day 7, with no effect of PBA (Fig 3A and 3B). Other metabolic genes involved in amino
acid biosynthesis and gluconeogenesis, such as Asns and Pck2, displayed no change in expres-
sion in response to Clenbuterol or PBA treatment (p>0.05; Fig 3A and 3B).
In contrast to our expectations based on previous work in pigs [9], Clenbuterol significantly
decreased mRNA expression of the stress-responsive transcription factors Atf4 and Atf5 at
days 3 (p<0.05) and 7 (p<0.01), with no effect of PBA (Fig 3C and 3D). Gene expression of
another stress-responsive transcription factor, Ddit3 (also known as Chop), was decreased by
Clenbuterol treatment at day 7 (p<0.05) but not day 3, with no effect of PBA (Fig 3C and 3D).
Fig 1. Effect of Clenbuterol and PBA on weight gain, feed efficiency, feeding behaviour and ambulatory activity. (A) Body weight
change with treatment and time. (B) Overall percentage body weight change following 21 days of treatment. (C) Total feed consumed during
21 days of treatment. (D) Gross feed efficiency (total body weight change divided by total feed consumed). (E) 24-hour cumulative food
intake following initial drug administration (day 0). (F) 24-hour cumulative food intake following drug administration on day 7. (G) 24-hour
ambulatory activity following initial drug administration (day 0). (H) 24-hour ambulatory activity following drug administration on day 7.
Asterisks denote a significant main effect of Clenbuterol:  p<0.001  p<0.0001. There was no significant effect of PBA.
https://doi.org/10.1371/journal.pone.0201481.g001
PBA and Clenbuterol-mediated muscle growth
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Other stress-responsive genes, Ddit1, Sesn2 and Cebpg, did not change with PBA or Clenbu-
terol treatment (p>0.05; Fig 3C and 3D), nor did PBA or Clenbuterol alter the expression of
X-box binding protein 1 (XBP1) variant 1 or Total XBP1 mRNA (Fig 3E and 3F), although
Clenbuterol did significantly reduce XBP1 variant 2 mRNA on day 3 (p = 0.004, Fig 3E), the
spliced variant induced as part of an ER stress response, as well as the ratio of variant 2: variant
1 on days 3 (p<0.001; Fig 3E) and 7 (p = 0.011; Fig 3F).
PBA inhibits the expression of integrated stress-responsive (ISR) genes in
cultured myotubes
In order to confirm that the PBA used was capable of inhibiting ER stress-induced gene expres-
sion, we determined its effects on thapsigargin-induced ER stress in vitro. C2C12 myotubes
were treated for 8 hours with 250nM thapsigargin, which caused a significant (p<0.0001)
increase in mRNA expression of several ISR genes (Psat1, Psph, Phgdh, Asns, Pck2, Atf4, Atf5,
Ddit1, Ddit3, Sesn2). As expected, co-treatment with 5mM PBA significantly (p<0.05) attenu-
ated, but did not completely block, the thapsigargin-induced increase in mRNA expression of
the majority of ISR genes (Fig 4A), with the exception of Ddit1. In contrast, the addition of PBA
alone, in the absence of thapsigargin, had no effect on the ISR gene expression (p>0.05; Fig 4A).
Effects of PBA on myotube size and myogenic differentiation in C2C12 cells
Although treatment with PBA in vivo had no significant effect on muscle weight or fibre size,
the addition of PBA (5mM) to the culture media of terminally differentiated C2C12 myotubes
Fig 2. Effect of Clenbuterol and PBA on individual muscle weights and TA muscle fibre diameters. (A) Relative Tibalis anterior muscle weight
(milligrams per gram of body weight). (B) Relative Extensor digitorum longus muscle weight (milligrams per gram of body weight). (C) Relative Soleus
muscle weight (milligrams per gram of body weight). (D) Relative Gastrocnemius muscle weight (milligrams per gram of body weight). (E) Percentage
frequency distribution of muscle fibre sizes analysed in Tibalis anterior muscle. (F) Average minimal feret’s diameter of Tibalis anterior muscle fibres. (G)
Representative images of WGA-stained Tibalis anterior muscle fibre cross-sections (20x magnification). Asterisks denote a significant main effect of
Clenbuterol:  p<0.05,  p<0.01,  p<0.0001. There was no significant effect of PBA.
https://doi.org/10.1371/journal.pone.0201481.g002
PBA and Clenbuterol-mediated muscle growth
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for 24 or 48 hours (repeated measures) resulted in significant myotube atrophy (p<0.0012),
whereas the vehicle treated myotubes maintained their size during this time frame (Fig 5A).
Global neoprotein synthesis was significantly decreased by PBA treatment at 24 and 48 hours
(Fig 5B and 5C; p<0.0001). An 8-hour treatment of differentiated myotubes with PBA revealed
a rapid and significant decrease in mRNA expression of all adult myosin heavy chain (MyHC)
isoforms (Myh7, Myh2, Myh1, Myh4) and also myogenin (Fig 5D), indicating that PBA might
impair the myogenic differentiation of C2C12 cells. Following treatment with PBA from day 0
or day 4 of differentiation, there were no significant (p>0.05) differences in nuclei number
(Fig 5G and 5H), but there was a significant (p<0.05) reduction in the number of nuclei
Fig 3. Effect of Clenbuterol and PBA on the expression of metabolic and stress-responsive genes in mouse muscle. (A) Day 3 mRNA
abundance of Cyclophillin (CYCLO), Phosphoserine aminotransferase 1 (PSAT1), Phosphoserine phosphatase (PSPH), 3-Phosphoglycerate
dehydrogenase (PHGDH), asparagene synthetase (ASNS), mitochondrial phosphoenolpyruvate carboxykinase (PCK2). (B) Day 7 mRNA
abundance of genes listed above (see A). (C) Day 3 mRNA abundance of Activating transcription factor 4 (ATF4), Activating transcription
factor 5 (ATF), Growth arrest and DNA damage inducible factor 45 alpha (DDIT1), Growth arrest and DNA damage inducible protein 153
(DDIT3), Sestrin-2 (SESN2). (D) Day 7 mRNA abundance of genes listed above (see C). (E) Day 3 mRNA abundance of Total X-box binding
protein 1 (XBP1), unspliced Variant 1 XBP1 (XBP1 Var1), spliced variant 2 XBP1 (XBP1 Var2) and the Variant ratio (Var 2/Var 1). (F) Day
7 mRNA abundance of genes listed above (see E). Asterisks denote a significant main effect of Clenbuterol:  p<0.05,  p<0.01, 
p<0.001,  p<0.0001. There was no significant effect of PBA.
https://doi.org/10.1371/journal.pone.0201481.g003
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residing within myosin heavy chain positive cells (Fig 5H and 5K), particularly when added
from day 0 (Fig 5H and 5I), again suggesting that PBA inhibits myogenic differentiation.
We also assessed whether the addition of fetal bovine serum (which is rich in growth fac-
tors) could alleviate PBA-induced myotube atrophy. Irrespective of serum content (0, 10 or
20% fetal serum), PBA treated myotubes were similar in size (p>0.05), whereas vehicle treated
myotubes were larger in the presence of 10 or 20% serum compared to 0% (Fig 5E and 5F;
p<0.01). This was confirmed using the 2 different methods of myotube size quantification, the
Myh4-promoter reporter system (Fig 5E) and MyHC/nuclei staining (Fig 5F).
Discussion
Our previous work highlighted induction of an integrated stress response (ISR) gene program
in skeletal muscle of pigs treated with a beta-adrenergic agonist [9]. An ISR in the context of
muscle growth is indicative of a perturbation to cellular homeostasis, likely caused by amino
acid limitation or endoplasmic reticulum (ER) stress. Hence we tested the hypothesis that the
ER-stress inhibitor, sodium 4-phenylbutyrate (PBA), would inhibit Clenbuterol-mediated
muscle growth in mice.
Firstly, co-administration of PBA to mice had no effect on the Clenbuterol-mediated
increase in muscle mass, muscle fibre diameter or feed conversion efficiency. Secondly, and
unexpectedly, with the exception of an increase in Psat1 mRNA expression, Clenbuterol
Fig 4. Effect of 5mM PBA on the expression of thapsigargin-inducible (ER-stress) genes in C2C12 myotubes. (A)
mRNA abundance of Phosphoserine aminotransferase 1 (PSAT1), Phosphoserine phosphatase (PSPH),
3-Phosphoglycerate dehydrogenase (PHGDH), asparagine synthetase (ASNS), mitochondrial phosphoenolpyruvate
carboxykinase (PCK2), Activating transcription factor 4 (ATF4), Activating transcription factor 5 (ATF), Growth
arrest and DNA damage inducible factor 45 alpha (DDIT1), Growth arrest and DNA damage inducible protein 153
(DDIT3), Sestrin-2 (SESN2). C2C12 myotubes (4-day differentiated) were treated with 250nM Thapsigargin (TG) in
the presence or absence of 5mM sodium 4-phenylbutyrate (PBA) for 8 hours. Expression of all genes was significantly
increased by thapsigargin (TG) treatment (p<0.0001). With the exception of DDIT1 and PCK2, there was a significant
effect of PBA on TG-induced expression of all genes (p<0.05). Asterisks denote the post-hoc Sidak’s multiple
comparisons test for a significant effect of PBA relative to No PBA within the control or Thapsigargin treated groups: 
p<0.05,  p<0.01,  p<0.0001.
https://doi.org/10.1371/journal.pone.0201481.g004
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Fig 5. Effects of PBA on C2C12 myotube size and differentiation. (A) Myotube width of MYH4 expressing cells following 0, 24 and 48 hours of
treatment with 5mM sodium 4-phenylbutuyrate (PBA). Measurements conducted on live cells expressing ZsGreen transcribed from an MYH4
promoter. (B) Global neoprotein synthesis (assessed by the relative incorporation of puromycin into nascent proteins) following 24 and 48 hours of
treatment with 5mM PBA. (C) Representative images of puromycin incorporation (for quantification see B). (D) Relative expression of myosin heavy
chain isoforms (MYH7, MYH2, MYH1, MYH4) and myogenin mRNA in myotubes treated with 5mM PBA for 8 hours. (E) Effect of differential fetal
serum content (0, 10 and 20%) in the presence or absence of 5mM PBA on myotube width. Measurements were conducted on live cells expressing
ZsGreen transcribed from an MYH4 promoter. (F) Effect of differential serum content (0, 10 and 20%) in the presence and absence of 5mM PBA on
myotube width. Measurements were conducted on fixed cells stained for myosin heavy chain (using MF20—green) and nuclei (using propodium
iodide—red). (G) Number of nuclei per field of view and (H) Percentage of nuclei residing in myosin heavy chain positive cells (myotubes) following
treatment with Vehicle (Ctrl) or 5mM PBA between days 0 and 4 of differentiation. (I) Representative images of Vehicle (Ctrl) and PBA (5mM)
treated C2C12 cells at day 4 of differentiation following staining for myosin heavy chain (using MF20—green) and nuclei (using propodium iodide—
red). (J) Number of nuclei per field of view and (K) Percentage of nuclei residing in myosin heavy chain positive cells (myotubes) following treatment
with Vehicle (Ctrl) or 5mM PBA between days 4 and 6 of differentiation. Asterisks in (D), (H) and (K) indicate a significant difference to the Ctrl (T-
test), whereas asterisks in (E) and (F) indicate a significant difference to 0% serum within the same treatment group (2-way ANOVA followed by
post-hoc Tukey’s multiple comparisons test):  p<0.05,  p<0.01,  p<0.001.
https://doi.org/10.1371/journal.pone.0201481.g005
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treatment (for 3 or 7 days) in mice failed to increase any of the 20+ ISR genes that were
increased by beta-adrenergic agonist treatment in pigs at the same time points [9]. On the con-
trary, expression of several ISR genes, including Atf4, Atf5, XBP1 variant 2 and Ddit3, were
actually significantly decreased by Clenbuterol treatment in mice. These data imply that,
unlike pigs, mice do not exhibit an ISR in response to administration of a beta-adrenergic ago-
nist. This highlights that translation of molecular events in murine skeletal muscle might not
be representative of that in large mammals. Indeed, others have shown that the skeletal muscle
transcriptome of mice administered with Clenbuterol (at days 1 and 10, time points different
to those used herein) [36] differed to the responses seen in pigs treated with a similar beta-
adrenergic receptor agonist (Ractopamine) [37]. Whilst it is clear that PBA does not influence
Clenbuterol mediated muscle growth in mice, the lack of a noticeable ISR gene program
induced by Clenbuterol makes it difficult to conclude that PBA would not influence Clenbu-
terol-mediated muscle growth in a large animal species, such as pigs, where a substantial ISR
gene program was observed [9,37].
There are several potential reasons for the disparity in ISR gene program induction in stud-
ies using rodents versus pigs, including the fact that different beta-adrenergic agonists have
been employed (Clenbuterol versus Ractopamine) and that the route of drug administration
was different (injected versus oral). However, we suspect the disparity is more likely due to dif-
ferences in the metabolism of mice compared to large mammals [38,39]. For instance, growing
mice and pigs have an ~3% and ~40% feed conversion efficiency, respectively, illustrating a
vast difference in basal metabolic rate between small and large mammals. Whilst increasing
the rate of growth (which was increased approximately 2-fold by Clenbuterol) is a metaboli-
cally demanding/stressful event, it is possible that small mammals, such as mice, are metaboli-
cally equipped to deal with such changes more readily than large mammals (like pigs or
humans). Indeed, unpublished data from our laboratory suggest that basal expression of sev-
eral ISR genes (particularly serine biosynthesis pathway genes) are more highly expressed in
mice versus pigs. As such, we suggest that mice might therefore not require the adaptive
molecular responses to beta-adrenergic agonists that have previously been observed in large
mammals, such as pigs [9,37].
Similar doses of PBA to those used herein (100mg/kg/day), ranging from 10mg/kg/day [40]
to 100mg/kg/day [41–43], have all previously been shown to attenuate an ISR in vivo, but only
when an ER stress was actually induced. Furthermore, we showed that PBA could limit induc-
tion of an ISR gene program in cultured muscle cells, but only when a known ER-stress
inducer (thapsigargin) was present. As such, we are confident that if an ISR had occurred dur-
ing Clenbuterol-mediated muscle growth, the dose of PBA used was sufficient to attenuate
such a response. It is noteworthy however, that previously published literature [40,41,44] indi-
cates that PBA does not suppress expression of ISR genes in the absence of induced-stress,
both in vivo and in vitro, which is presumably why we saw no effects of the PBA in vivo.
When testing the efficacy of PBA to block a thapsigargin-induced ISR gene program in
vitro, we noticed that prolonged treatment with PBA alone caused profound myotube atrophy,
which is in agreement with a recent in vivo study [28]. Whilst 21 days of PBA treatment in vivo
did not cause statistically significant muscle atrophy, there was a noticeable reduction in mus-
cle fibre diameters with PBA compared to that of the controls and other treatments. Bohnert
et al [28] showed that when the same dose of PBA was administered daily to mice for 28 days,
it significantly decreased muscle mass and muscle fibre diameters. It is possible that 3 weeks of
PBA treatment is insufficient to observe a significant muscle atrophy phenotype in vivo, but
that longer (28d) administration of PBA is indeed detrimental to the maintenance of muscle
mass. This has serious implications for patients receiving chronic doses of PBA for the treat-
ment of urea cycle disorders, suggesting that they should be monitored accordingly.
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When examined in vitro, we, and others [28], show that PBA inhibits global neoprotein syn-
thesis in muscle cells, which is most likely responsible for the reduction in myotube size.
Expanding on this, we show that PBA drastically inhibits mRNA expression of myogenin
and all myosin heavy chain isoforms in vitro within 8 hours of treatment, during which,
expression of ISR genes was not altered. This implies that PBA affects myogenic differentiation
in cultured muscle cells, independent of altering an ISR gene program. It is noteworthy how-
ever, that whilst a high dose of PBA (5mM) is required to attenuate ER-stress in cultured cells
[28,40,44,45], in vivo concentrations of 5mM PBA in the muscle are unlikely. The plasma half-
life of PBA in mice is very short (within minutes for moderate doses) [46]. Even when high
doses of PBA (36g/day) were administered to humans, plasma PBA concentrations only
reached ~1mM, which lasted less than 4 hours [23]. However, in vitro data generated by us,
and others [28,40,44,45], using high (5mM) PBA concentrations may be representative of
chronic exposure to PBA in vivo. Another key difference that might relate to differential
responses to PBA is that in vivo skeletal muscle consists mainly of terminally differentiated
muscle fibres, whereas in vitro cultures of C2C12 cells are a mix of early stage differentiated
myotubes and undifferentiated myoblasts. Since PBA was shown to inhibit myogenic differen-
tiation in vitro, then similar effects are unlikely in adult animals, where myogenic differentia-
tion is virtually complete. However, there may be effects observed if PBA were administered in
vivo during fetal development or after muscle damage when satellite cells are activated and
undergo myogenic differentiation.
Finally, we show that the initial administration of Clenbuterol to mice, with or without
PBA, drastically inhibited food intake and delayed the onset of ambulatory activity in the dark
phase. To the best of our knowledge, this very early response to Clenbuterol has not previously
been reported. Accordingly, any metabolic or molecular analyses conducted on mice within
24 hours of initial administration of this drug should be interpreted with caution, as they are
likely to be influenced by these behavioural and consequent metabolic changes.
In summary, contrary to our hypothesis Clenbuterol did not induce an integrated stress
response (ISR) gene program in mouse muscle, but it did increase PSAT1 mRNA expression,
as seen in our previous pig study. Indeed, Clenbuterol actually reduced expression of several
ISR genes in mouse skeletal muscle. Co-administration of PBA had no effect on Clenbuterol-
mediated muscle growth or gene expression in mice, but PBA did inhibit the thapsigargin-
induced ISR gene expression in cultured C2C12 muscle cells and appeared to inhibit myogenic
differentiation independent of altering ISR gene expression. There are clear differences
between mice and pigs in the molecular responses to beta-agonists, as well as differences
between C2C12 muscle cells and mouse skeletal muscle in their response to PBA.
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